Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review
Open Access
- 1 April 2018
- journal article
- review article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 2287-2293
Abstract
Dove Press is a member of the Open Access Initiative, specializing in peer reviewed Medical Journals. View articles or submit your research for publishing.Keywords
This publication has 39 references indexed in Scilit:
- Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term SurvivorsJournal of Clinical Oncology, 2013
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II StudyJournal of Clinical Oncology, 2012
- Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL StudyJournal of Clinical Oncology, 2011
- Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell LymphomaJournal of Clinical Oncology, 2009
- Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter StudyJournal of Clinical Oncology, 2009
- International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical OutcomesJournal of Clinical Oncology, 2008
- Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell LymphomaClinical Cancer Research, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Synthesis and Biological Activity of a Novel Class of Purine Nucleoside Phosphorylase InhibitorsNucleosides, Nucleotides & Nucleic Acids, 2000
- NUCLEOSIDE-PHOSPHORYLASE DEFICIENCY IN A CHILD WITH SEVERELY DEFECTIVE T-CELL IMMUNITY AND NORMAL B-CELL IMMUNITYThe Lancet, 1975